Traws Pharma, Inc. (NASDAQ:TRAW) Given Average Rating of “Reduce” by Brokerages

Shares of Traws Pharma, Inc. (NASDAQ:TRAW) have received an average recommendation of “Reduce” from the five ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation and three have issued a hold recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $1.00.

Several research firms recently weighed in on TRAW. HC Wainwright reiterated a “negative” rating and set a $1.00 price objective on shares of Traws Pharma in a research note on Thursday, June 18th. Weiss Ratings lowered Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a report on Friday, May 29th. LADENBURG THALM/SH SH cut Traws Pharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 15th. Wall Street Zen raised Traws Pharma from a “strong sell” rating to a “sell” rating in a report on Saturday, June 13th. Finally, Citigroup lowered Traws Pharma to a “neutral” rating in a research report on Monday, June 15th.

Institutional Investors Weigh In On Traws Pharma

A number of hedge funds have recently added to or reduced their stakes in TRAW. Geode Capital Management LLC grew its position in shares of Traws Pharma by 41.9% during the fourth quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock worth $70,000 after acquiring an additional 18,213 shares during the last quarter. Ikarian Capital LLC increased its holdings in shares of Traws Pharma by 2,280.0% in the 4th quarter. Ikarian Capital LLC now owns 678,142 shares of the company’s stock worth $766,000 after acquiring an additional 649,649 shares during the period. Squadron Capital Management LLC bought a new stake in Traws Pharma in the 4th quarter valued at about $806,000. Adage Capital Partners GP L.L.C. boosted its stake in Traws Pharma by 121.2% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 730,000 shares of the company’s stock valued at $825,000 after purchasing an additional 400,000 shares during the period. Finally, Boothbay Fund Management LLC acquired a new position in Traws Pharma during the 4th quarter valued at about $220,000. 7.95% of the stock is currently owned by institutional investors.

Traws Pharma Price Performance

Shares of TRAW opened at $0.66 on Friday. The stock has a market capitalization of $10.06 million, a PE ratio of -0.39 and a beta of 1.51. The business’s fifty day moving average price is $1.18 and its 200 day moving average price is $1.54. Traws Pharma has a 12-month low of $0.64 and a 12-month high of $3.27.

Traws Pharma (NASDAQ:TRAW) last issued its earnings results on Friday, May 15th. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.39. As a group, research analysts anticipate that Traws Pharma will post -1.43 earnings per share for the current fiscal year.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.